|AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer|
- Published in the peer-reviewed journal Oncotarget –
- Potential applications in scarless tissue regeneration, cancer, and aging -
“It is rare to find genes implicated in tissue regeneration, let alone
with abnormal expression in so many diverse cancer types such as those
of the breast, lung, kidney, bone, and muscle,” said
A short video is available online describing the discovery and its implication for product development at AgeX. Included in the video is a discussion of an iTR product designated RenelonTM, which, in its first generation form, utilizes a repurposed drug and may therefore have a relatively short development timeline.
“The embryonic-to-fetal transition (EFT) deciphered in this study is
emerging as a wonderful new arena in which to explore the enhancement of
regenerative capacity in old age, which is the core of AgeX’s mission,”
“BioTime and AgeX Therapeutics are at the forefront of regenerative
Background on Induced Tissue Regeneration
The leading unsolved problem in medicine as the year 2018 arrives
remains the inability of the adult human body to regenerate tissues
affected by injury or disease. It is estimated that approximately 80% of
Adult humans, like most mammals, have only a limited capacity to repair tissues in the body resulting from trauma or degenerative disease. However, in some species, such as the Mexican salamander, there exists a profound capacity to regenerate injured tissues, even amputated limbs. Recent studies suggest that this power reflects a capacity present early in life and largely lost by the time we are born.
Using the Company’s proprietary pluripotent stem cell-based platform,
The study resulted in the identification of genes differently expressed during the time tissues can regenerate compared to later in life when that capacity is impaired. One gene highlighted in the study is designated COX7A1 which is thought to play a role in energy metabolism along with other critical functions in the cell. Consistent with a role of COX7A1 in regeneration and cancer, the gene appeared to be profoundly dysregulated in a broad array of cancer cell types, suggesting cancer may be thought of as “regeneration out of control.” As a result, the discoveries reported in today’s publication may have the potential to lead to the ability to induce scarless tissue regeneration in humans, as well as point to new strategies for the diagnosis and treatment of cancer.
The publication titled “Use of deep neural network ensembles to identify
embryonic-fetal transition markers: repression of COX7A1 in
embryonic and cancer cells” (Oncotarget,
About AgeX Therapeutics
BioTime is a late-stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. Submission for approval of Renevia® in the EU is expected to be early 2018, with possible approval and commercial launch in 2018. There were no device related serious adverse events reported. OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn,
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to product technology, clinical development, regulatory approval timelines, the success of potential cosmetic applications and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
Investor Contact for BioTime: